Trial Profile
ACH471-001; A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0144471 in Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Danicopan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; First in man
- Sponsors Achillion Pharmaceuticals
- 19 May 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT04889677).
- 12 May 2021 Planned End Date changed from 30 Aug 2016 to 21 Jun 2016.
- 05 Oct 2016 Status changed from recruiting to completed.